1-bromo-2-(2-methoxybenzyl)benzene | 1287721-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-2-(2-methoxybenzyl)benzene
• 英文别名: 1-bromo-2-[(2-methoxyphenyl)methyl]benzene
• CAS: 1287721-19-0
• 化学式: C₁₄H₁₃BrO
• 分子量: 277.161
• InChiKey: OERNXJDAYZRLGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.05
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.23
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  1-bromo-2-(2-methoxybenzyl)benzene 在 palladium diacetate 、 cesium pivalate 、 三环己基膦 作用下， 以 四氢呋喃 为溶剂， 反应 12.08h， 以93%的产率得到1-methoxy-9H-fluorene
  参考文献：
  名称：

  钯催化的C（sp 2）–H活化活化合成芴†

  摘要：

  通过钯催化2'-卤代-二芳基甲烷通过芳基CH键的活化环化反应，已经开发出一种简便的芴衍生物合成方案。反应进行得很顺利，并使富电子和电子不足的底物都能以良好或优异的产率转化为相应的芴。研究表明，这种Pd催化的环化反应也可用于2'-氯-二芳基甲烷的底物，并且2'-碘-二苯基甲烷不会发生催化剂中毒。

  DOI：

  10.1039/c6nj02033j
• 作为产物：
  描述：

  (2-溴苯基)(2-甲氧基苯基)甲醇 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-bromo-2-(2-methoxybenzyl)benzene
  参考文献：
  名称：

  邻炔基二芳基甲烷的环异构化反应铋催化蒽的合成

  摘要：

  在这项研究中，蒽利用一种新颖的方法从邻-炔基二芳基甲烷中高效合成，该方法利用了Bi（OTf）3作为催化剂与三氟乙酸（TFA）的协同作用。通过该反应，我们在温和条件下实现了快速高效合成具有各种官能团的蒽。

  DOI：

  10.1016/j.tetlet.2015.10.111

文献信息

• <i>N</i>-Hydroxyphthalimide-Mediated Electrochemical Iodination of Methylarenes and Comparison to Electron-Transfer-Initiated C–H Functionalization
  作者：Mohammad Rafiee、Fei Wang、Damian P. Hruszkewycz、Shannon S. Stahl

  DOI：10.1021/jacs.7b09744

  日期：2018.1.10

  electrochemical method has been developed for selective benzylic iodination of methylarenes. The reactions feature the first use of N-hydroxyphthalimide as an electrochemical mediator for C-H oxidation to nonoxygenated products. The method provides the basis for direct (in situ) or sequential benzylation of diverse nucleophiles using methylarenes as the alkylating agent. The hydrogen-atom transfer mechanism for

  已经开发了一种用于甲基芳烃的选择性苄基碘化的电化学方法。该反应的特点是首次使用 N-羟基邻苯二甲酰亚胺作为 CH 氧化为非氧化产物的电化学介质。该方法为使用甲基芳烃作为烷化剂对不同亲核试剂进行直接（原位）或顺序苄基化提供了基础。CH 碘化的氢原子转移机制允许 CH 氧化在对基板电子特性的依赖性最小的情况下进行，并且电极电位比直接电化学 CH 氧化低 0.5-1.2 V。
• Tin exchanged heteropoly tungstate: An efficient catalyst for benzylation of arenes with benzyl alcohol
  作者：Ch. Ramesh Kumar、K.T. Venkateswara Rao、P.S. Sai Prasad、N. Lingaiah

  DOI：10.1016/j.molcata.2011.01.008

  日期：2011.3

  The partial exchange of tin with the protons of 12-tungstophosphoric acid (TPA) results in a highly active heterogeneous catalyst for benzylation of arenes with benzyl alcohol as benzylating agent. The catalysts were characterized by X-ray diffraction, Laser-Raman and FT-IR of pyridine adsorption. The catalytic activity depends significantly on the extent of tin exchanged with the protons of heteropoly tungstate. The characterization results suggest the presence of Lewis acidic sites by the exchange of tin. The catalyst with partial exchange of Sn showed high benzylation activity, which in turn related to variation in acidity of the catalysts. The catalyst is highly active for benzylation reaction irrespective of the nature of substituted arenes and benzyl alcohols. These catalysts are highly active compared to other acid catalysts used for benzylation of different arenes. The catalyst is easy to separate from reaction mixture and exhibit consistent activity upon reuse. The plausible reaction mechanism based on the role of both Lewis and Bronsted acid sites of the catalyst was discussed. (C) 2011 Elsevier B.V. All rights reserved.
• [EN] TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE TAAR1 ET DE SÉROTONINE, ET COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]SUNOVION PHARMACEUTICALS INC.

  公开号：WO2022217265A1

  公开（公告）日：2022-10-13

  Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R1, R2, X1, X2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, and Y8) are as disclosed herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of using the compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions of the foregoing, e.g., to treat a neurological or psychiatric disease or disorder.